Amenamevir

Innovative antiviral medication targeting viral helicase-primase complex, offering an alternative for resistant viral strains.

Treatment of herpes simplex, recurrent herpes simplex, and herpes zoster.

Anti-viral drugs

Viral helicase-primase inhibitor

Inhibits viral helicase-primase complex essential for viral DNA replication, distinct from DNA polymerase inhibitors.

Suppression of viral DNA replication through helicase-primase inhibition.

Herpes simplex: 200 mg once daily after meals. Recurrent herpes simplex: 1200 mg single dose within 6 hours. Herpes zoster: 400 mg once daily after meals.

Oral administration after meals.

Take as soon as remembered.

Headache, nausea, diarrhea, abdominal pain, thrombocytopenia, gingival bleeding, palpitations.

Special monitoring essential for severe renal impairment, thrombocytopenia, and elderly patients.

Contraindicated in severe renal impairment and hypersensitivity.

Interacts with CYP3A4 inhibitors (Ketoconazole) and inducers (Rifampicin); affects Midazolam.

To be taken after meals.

Animal studies showed no adverse fetal effects, but human data is limited.

Pregnancy Category: N/A — always consult a doctor before taking during pregnancy.

No specific information available during breastfeeding.

Lack of specific clinical studies in children.

Special monitoring essential for elderly patients.

Contraindicated in severe renal impairment.

Supportive care as needed.

Store below 30°C in a dry place, away from light and moisture.

Amenamevir